Literature DB >> 28983027

China sprints ahead in CRISPR therapy race.

Dennis Normile1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28983027     DOI： 10.1126/science.358.6359.20

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  8 in total

1.  Unexpected CRISPR on-target effects.

Authors:  Hyunji Lee; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2018-07-30       Impact factor: 54.908

Review 2.  Genome Editing: A New Horizon for Oral and Craniofacial Research.

Authors:  N Yu; J Yang; Y Mishina; W V Giannobile
Journal:  J Dent Res       Date:  2018-10-24       Impact factor: 6.116

Review 3.  CRISPR/Cas9 System: A Potential Tool for Genetic Improvement in Floricultural Crops.

Authors:  Ujjwal Sirohi; Mukesh Kumar; Vinukonda Rakesh Sharma; Sachin Teotia; Deepali Singh; Veena Chaudhary; Manoj Kumar Yadav
Journal:  Mol Biotechnol       Date:  2022-06-25       Impact factor: 2.860

Review 4.  Applications of Alternative Nucleases in the Age of CRISPR/Cas9.

Authors:  Tuhin K Guha; David R Edgell
Journal:  Int J Mol Sci       Date:  2017-11-29       Impact factor: 5.923

Review 5.  Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy.

Authors:  Qian Li; Zhou Qin; Qingnan Wang; Ting Xu; Yang Yang; Zhiyao He
Journal:  Comput Struct Biotechnol J       Date:  2019-06-08       Impact factor: 7.271

6.  Responsible governance of human germline genome editing in China†.

Authors:  Yaojin Peng; Jianwei Lv; Lulu Ding; Xia Gong; Qi Zhou
Journal:  Biol Reprod       Date:  2022-07-25       Impact factor: 4.161

Review 7.  Blossom of CRISPR technologies and applications in disease treatment.

Authors:  Huayi Liu; Lian Wang; Yunzi Luo
Journal:  Synth Syst Biotechnol       Date:  2018-10-22

Review 8.  Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety.

Authors:  Lydia Teboul; Yann Herault; Sara Wells; Waseem Qasim; Guillaume Pavlovic
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.